Please login to the form below

Not currently logged in
Email:
Password:

FDA recommends J&J’s stroke-prevention drug

The FDA has recommended Xarelto (rivaroxaban) for stroke prevention in patients with the heart condition nonvalvular atrial fibrillation

The Food and Drug Administration (FDA) has recommended Xarelto (rivaroxaban) for stroke prevention in patients with the heart condition nonvalvular atrial fibrillation.

Johnson & Johnson, which partnered with Bayer to develop Xarelto, had previously gained approval for its use in reducing the risk of blood clots, deep vein thrombosis (DVT), and pulmonary embolism (PE) following knee or hip replacement surgery.

The drug received a positive endorsement from the FDA, despite receiving a critical FDA review two days earlier.

A study into Xarelto as a stroke-prevention drug demonstrated that it was as good as other drugs currently being used. However, when switching from Xarelto to another drug, there is a spike of adverse effects, which has not been fully studied yet.

The ease of taking Xarelto (which is administered as one 20mg pill daily) compares favourably to other treatments, as neither International Normalized Ratio (INR) monitoring nor dietary restrictions are necessary.

13th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics